Neovacs S.A ROCE
What is the ROCE of Neovacs S.A?
The ROCE of Neovacs S.A. is 0.00%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with roce similar to Neovacs S.A
- Omega Alpha Spac has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Elemental Royalties Ltd has ROCE of -0.01%
- Auburn National Bancorp has ROCE of -0.01%
- Galaxy Digital has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Neovacs S.A has ROCE of 0.00%
- Tejon Ranch Co has ROCE of 0.01%
- Glen Burnie Bancorp has ROCE of 0.02%
- MSP Steel & Power has ROCE of 0.02%
- TTL Beteiligungs- und Grundbesitz-AG has ROCE of 0.03%
- First Foundation Inc has ROCE of 0.03%
- FirstMark Horizon Acquisition has ROCE of 0.03%